Main human AOD-9604 treatment timelines Study METAOD004 Participants 36 Route Oral Treatment length 7 days Dose range 9, 27, or 54 mg/day Main lesson Short safety and tolerability study Study METAOD005 Participants 300 Route Oral Treatment length 12 weeks Dose range 1 to 30 mg/day Main lesson Earlier weight-loss trial with a non-linear dose response Study METAOD006 Participants 502 randomized Route Oral Treatment length 24 weeks Dose range 0.25, 0.5, or 1 mg/day Main lesson Primary weight-loss goal was not met The oral milligram doses in these trials cannot be converted into subcutaneous microgram doses
whatever it is, it's your one and only shot at getting calories into them until you can get to the vet
doi:10.1016/j.ejca.2005.11.014 27Arnault JP, Wechsler J, Escudier B,
This means: It is banned in-competition and out-of-competition Detection in drug testing can result in suspension, disqualification, or loss of eligibility BPC-157 is not typically detected in standard panels , but advanced screens may be used at the elite level Any pharmacological substance which is not addressed by any of the subsequent sections of the list and with no current approval by any governmental regulatory health authority for human therapeutic use is prohibited. World Anti-Doping Agency (WADA), Prohibited List International Status The legality of BPC-157 varies widely by country
Dis Markers (2019) 2019:2073139
